newsfilter
← Latest News
GlobeNewswire·

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean